New Delhi: Lupin on Tuesday said it has received final approval from the US Food and Drug Administration to market Blisovi oral contraceptive tablets in different strengths in the American market.
"The company has received final approvals from the United States Food and Drug Administration (US health regulator) to market generic versions of Warner Chilcott's Loestrin Fe 1/20 tablets and Loestrin Fe 1.5/30 tablets", Lupin said in a statement.
Lupin's US subsidiary - Lupin Pharmaceuticals Inc - shall commence promoting the product in the US shortly, it added.
The tablets are indicated for prevention of pregnancy in women who chose to use oral contraceptives.
According to IMS MAT data, Loestrin Fe 1/20 had US sales of $139.7 million while Loestrin Fe 1.5/30 had sales of $55.5 million.
Shares in Lupin, on Tuesday, ended 1.12 per cent higher at Rs 1,860.35 apiece on the BSE, whose benchmark Sensex index finished down 0.17 per cent.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.